Belinchón-Romero, Isabel http://orcid.org/0000-0002-6007-7320
Bellot, Pablo http://orcid.org/0000-0001-8307-1813
Romero-Pérez, David http://orcid.org/0000-0003-1875-6722
Herraiz-Romero, Isolina http://orcid.org/0000-0003-4950-3189
Marco, Francisco http://orcid.org/0000-0001-5113-3637
Frances, Rubén http://orcid.org/0000-0001-5105-1201
Ramos-Rincón, José-Manuel http://orcid.org/0000-0002-6501-9867
Funding for this research was provided by:
Institute of Health and Biomedical Research of Alicante (ISABIAL)/FISABIO Foundation (180140)
Innovation Prize in the Health Field of Celgene of the University of Alcalá de Henares
Article History
Received: 17 January 2021
Accepted: 6 April 2021
First Online: 21 April 2021
Competing interests
: I.B.R. acted as a consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen Amgen, Leo-Pharma, Pfizer-Wyeth, MSD, and UCB. The rest of the authors state do not declare conflicts of interest.